摘要
目的观察慢性肾脏病（CKD）2、3期局灶节段性肾小球硬化（FSGS）患者应用霉酚酸酯治疗的作用。方法对我院16例CKD2、3期的FSGS患者用霉酚酸酯1．5g·d^-1口服治疗6个月后，渐减量至0．5g·d^-1维持。监测0、6、12、18个月内生肌酐清除率、尿蛋白定量，并与同期未给予霉酚酸酯治疗的17例患者进行比较。结果霉酚酸酯治疗组12个月后，内生肌酐清除率下降速率较对照组减慢，差异有统计学意义；蛋白尿减少，血清白蛋白上升，但与对照组比较，差异无统计学意义。结论对已经出现肾功能损害的FSGS患者，霉酚酸酯治疗可延缓肾功能损害的进展，这种作用不完全依赖于蛋白尿的减少。
Objective To study the effects of Mycophenolate Mofetil（MMF） on Focal segmental glomerulosclerosis（FSGS）patients in chronic kidney disease （CKD） stages 2 and 3. Method 16 FSGS patients in CKD stages 2 and 3 were treated with MMF. MMF 1.5 g·d^-1 were given in the first 6 months. The drug dosage was decreased gradually with maintence dose of 0. 5 g·d^-1. CCR and urinary protein excretion were detected at 0, 6, 12, 18 month after tceatment. And compared with 17 FSGS patients in CKD stages 2 and 3 without MMF treatment. Results The speed of decrease of CCR in MMF treated group was slower as compare to control group, the difference had statistic significance （P〈0.01）. The urinary protein excretion in MMF treated group was also decreased and serum albumin was increased, but showed no statistic significance （P〉0. 05）. Conclusions MMF can delay the progress of FSGS patients with renal dysfunction, this effect is not proteinuria dependant.
出处
《临床肾脏病杂志》
2007年第6期254-255,共2页
Journal Of Clinical Nephrology
关键词
肾小球硬化
病灶性
霉酚酸酯
肾
内生肌酐清除率
Glomerulosclerosis, focal
Mycophenolate Mofetil （MMF）
Kidney, Creatinine clearance clearavce
